Posts By :

admin

Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux
Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux 150 150 Lysogene

Paris, France — 15 January 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…

Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene
Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene 150 150 Lysogene

Paris, France — 18 December 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a phase…

Lysogene Reports its Cash Position as of 30 September 2020
Lysogene Reports its Cash Position as of 30 September 2020 150 150 Lysogene

Cash and cash equivalents of €22.1 million1 as of 30 September 2020 Paris, France —…

Lysogene provides update on the AAVance Clinical Trial Evaluating LYS- SAF302 in Patients with MPS IIIA
Lysogene provides update on the AAVance Clinical Trial Evaluating LYS- SAF302 in Patients with MPS IIIA 150 150 Lysogene

Paris, France — 15 October 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a Phase…

Lysogene: First Half 2020 Business Update
Lysogene: First Half 2020 Business Update 150 150 Lysogene

Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…

Lysogene announces a research collaboration with the Weizmann Institute of Science
Lysogene announces a research collaboration with the Weizmann Institute of Science 150 150 Lysogene

Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting
LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting 150 150 Lysogene

Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA 150 150 Lysogene

Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)
NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product This agreement covers the manufacturing of the Adeno-Associated Virus (AAV) 150 150 Lysogene

Lyon and Paris, France, May 26, 2020 – Novasep, a leading supplier of services and…

LYSOGENE Annual Ordinary and Extraordinary General Meeting of 26 June 2020 Availability of the Preparatory Documents
LYSOGENE Annual Ordinary and Extraordinary General Meeting of 26 June 2020 Availability of the Preparatory Documents 150 150 Lysogene

Paris, France — 20 May 2020 at 06:00pm CEST— Lysogene (FR0013233475 – LYS), a Phase…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top